RE: Presentations18 Oct 2022 11:06
By Zak Mir:
Evgen
“Drug development group Evgen Pharma (EVG), saw its shares maintain most of its recent gains as it announced the start of a pharmacokinetic/pharmacodynamic trial and that it will commence an Investigator Sponsored clinical study for the glioblastoma programme. The kicker here was including the magic acronym FDA in the RNS. This came after a SFX-01 licensing deal for up to $160.5m. Given that the market cap is currently £13m, some may say the market is adopting a wait and see stance.“